Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2- Breast Cancer at a Single Cancer Center.

Oncologist · 2022 · PMC9355808 · PMID 35666660

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

In the treatment of HR+/HER2− metastatic breast cancer CDK4/6 inhibitors were considered highly significant in delaying the utilization of chemotherapy and enhancing patient quality of life.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.